Rare Diseases Market– Our New Study Reveals Trends, R&D Progress, and Predicted Revenues over the Next Decade
The global rare diseases market was valued at US$xx billion in 2021 and is likely to reach US$xx billion by 2026 growing at a CAGR of xx% from 2021-2026. Furthermore, the market is predicted to generate revenue of US$xx billion by 2031. Increasing cases of rare genetic diseases coupled with rising number of US FDA approvals for treatment of rare diseases is likely to promote the market growth. The growing emphasis on scientific activities and the development of new medicinal medicines has expanded the market importance of treating rare diseases.
What Are The Market Driving Factors?
• Increasing number of approvals for rare diseases
• Robust pipeline by major players
• Increasing health awareness
What Are The Market Opportunities?
• Increasing demand from emerging economies
• Increasing government support
Some of the novel drugs approved in 2020 for rare diseases
• Evrysdi
• Lampit
• Orladeyo
• Artesunate
In addition, increasing product advances are contributing to the launch of ground-breaking technical instruments for the detection of unusual genetic disorders. In addition, supportive government initiatives aimed at increasing recognition of the treatment of rare diseases are contributing to expanded implementation of successful rare disease therapies. In terms of drugs, others segment dominated the global market by generating revenue of US$xx billion in 2021 and is likely to grow at a CAGR of xx% over the forecast period.
Key highlights about rare diseases market:
• Majority of rare diseases effect new born and are diagnosed before the age of 5 years
• Genetic testing finds major application in diagnosing variety of rare diseases
• Rising number of new born screenings is expected to increase the diagnosis rate of rare diseases
• Prenatal screening finds its application in diagnosing Trisomy 13, Trisomy 18 and Edward’s disease
Discover how to stay ahead
Our 330+ pages report provides 400+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Rare Diseases Market. See how to exploit the opportunities.
Rare Diseases Market Segmentation
Drugs
• Revlimid
• MabThera/Rituxan
• Opdivo
• Imbruvica
• Sprycel
• Tasigna
• Copaxone
• Rebif
Disease
• Rare Oncology Diseases
• Rare Metabolic Diseases
• Rare Neurologic Diseases
• Rare Hematology Diseases
• Rare Infectious Diseases
• Other Rare Diseases
Type
• Non Biologics
• Biologics
Age
• Adult
• Pediatric
End use
• Specialty Pharmacies
• Hospital Pharmacies
• Retail Pharmacies
Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
Need industry data? Please contact us today.
COVID-19 Impact Recovery Scenarios
This report includes Baseline Forecasts along with Different Rebound Scenarios to help analyze the global rare disease market-no matter how COVID-19 affects the economy.
To access the data contained in this document please email contactus@visiongain.com
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.
Leading countries and the potential for market growth
Overall world revenue for rare disease Market will surpass $xx billion in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Rare Disease Market report helps you
In summary, our 330+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for rare disease Market, with forecasts for disease and end use, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 17 key national markets– See forecasts for the rare disease market in North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Also forecasted is the market in the U.S., Canada, UK, France, Germany, Italy, Spain, Russia, Denmark, Netherland, Japan, India, China, Brazil, Mexico, South Africa, and UAE among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 15 of the major companies involved in the rare disease Market. Some of the companies profiled in this report are Pfizer Inc., Novartis AG, Merck KGaA, F. Hoffmann-La Roche Ltd, Amgen Inc., Biogen Inc., Teva Pharmaceuticals, Alexion Pharmaceuticals, Inc., Sanofi S.A., AbbVie, Bristol Myers Squibb, Takeda Pharmaceuticals, Roche, Johnson & Johnson Services, Inc.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the rare disease market and leading companies. You will find data, trends, and predictions.
Who should read this report?
• Senior Executives
• Business Development Managers
• Marketing Directors
• Consultants
• Chief Executive Officers
• Governments, agencies & organizations actively working or interested in the rare disease industry will also find significant value in our research.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Rare Diseases Market Report 2021-2031: Forecasts by Drugs (Revlimid, MabThera/Rituxan, Opdivo, Imbruvica, Sprycel, Tasigna, Copaxone, Rebif), by Disease (Rare Oncology Diseases, Rare Metabolic Diseases, Rare Neurologic Diseases, Rare Haematology Diseases, Rare Infectious Diseases, Other Rare Diseases), by Type (Non Biologics, Biologics), by Age (Adult, Pediatric), by End-use (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Introduction to Rare Diseases Market
1.2 The Orphan Drug Act
1.2.1 What is the Orphan Drug Act?
1.2.2 What is an orphan drug?
1.2.3 How does the FDA encourage the development of medical products to diagnose and treat rare diseases?
1.2.4 What does the FDA Office of Orphan Products Development do?
1.2.5 How do the FDA medical product centers support rare disease product development?
1.3 Types of Rare disease
1.4 Why You Should Read This Report
1.5 What This Report Delivers
1.6 Key Questions Answered By This Analytical Report Include:
1.7 Who is This Report For?
1.8 Methodology
1.8.1 COVID-19 Impact: Recovery Scenarios
1.8.2 Market Evaluation & Forecasting Methodology
1.9 Frequently Asked Questions (FAQs)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2 Executive Summary
3 Industry Insights
3.1 Drivers
3.1.1 Increasing number of approvals for rare diseases
3.1.2 Robust pipeline by major players
3.1.3 Increasing health awareness
3.2 Restraints
3.2.1 High R&D costs
3.3 Opportunities
3.3.1 Increasing demand from emerging economies
3.3.2 Increasing government support
3.4 Threats
3.4.1 Uncertain R&D Results
3.4.2 High entry barriers
3.5 SWOT Analysis
3.6 Porter’s Five Forces Analysis
3.6.1 Bargaining Power of Buyers (Low)
3.6.2 Bargaining Power of Suppliers (medium)
3.6.3 Threat of Substitutes (Low)
3.6.4 Threat of New Entrants (Low)
3.6.5 Industry Rivalry (High)
3.7 Novel drugs approved in 2020 for rare diseases
3.8 The Impact of COVID-19 on rare disease clinical trials
4 Rare Diseases Market by Drugs
4.1 Revlimid Segment Market Forecast, 2021-2031
4.1.1 Rising number of new cases getting diagnosed with multiple myeloma to support growth
4.2 MabThera/Rituxan Segment Market Forecast, 2021-2031
4.2.1 Rheumatoid arthritis to fuel market demand
4.3 Opdivo Segment Market Forecast, 2021-2031
4.3.1 Combiantion drug therapy to support market demand
4.4 Imbruvica Segment Market Forecast, 2021-2031
4.4.1 Rising incidence of B cell cancers to boost demand
4.5 Sprycel Segment Market Forecast, 2021-2031
4.5.1 Improving diagnosis rate of acute lymphoblastic leukaemia to rise demand in future
4.6 Avonex Segment Market Forecast, 2021-2031
4.6.1 Positive advent in clinical trials for multiple disorders to fuel market growth
4.7 Tasigna Segment Market Forecast, 2021-2031
4.7.1 Increasing demand to overcome imatinib resistace to increase market revenue
4.8 Copaxone Segment Market Forecast, 2021-2031
4.8.1 Complications associated with relapsing MS to support market development
4.9 Rebif Segment Market Forecast, 2021-2031
4.9.1 Rising cases of relapsing MS to increase market demand
4.10 Gleevec Segment Market Forecast, 2021-2031
4.10.1 Increasing demand for rare cancer medication
4.11 Velcade Segment Market Forecast, 2021-2031
4.11.1 Generic completion to hinder market growth
4.12 Others Segment Market Forecast, 2021-2031
5 Rare Diseases Market by Disease
5.1 Rare Oncology Diseases Segment Market Forecast, 2021-2031
5.1.1 Increasing Target Population Getting Diagnosed With Rare Cancers
5.1.2 Recovery Scenarios (V, U, W, L)
5.2 Rare Metabolic Diseases Segment Market Forecast, 2021-2031
5.2.1 Advancements in gene therapy to fuel rare metabolic diseases segment
5.2.2 Recovery Scenarios (V, U, W, L)
5.3 Rare Neurologic Diseases Segment Market Forecast, 2021-2031
5.3.1 Advent of genome sequencing to fuel rare neurological disease market
5.3.2 Recovery Scenarios (V, U, W, L)
5.4 Rare Hematology Diseases Segment Market Forecast, 2021-2031
5.4.1 Increased blood-related diseases such as leukaemia, sickle cell anaemia, and myeloma continue to contribute market growth
5.4.2 Recovery Scenarios (V, U, W, L)
5.5 Rare Infectious Diseases Segment Market Forecast, 2021-2031
5.5.1 Advanced Healthcare Infrastructure in Developed and Emerging Countries to Fuel Rare Infectious Disease Segment
5.5.2 Recovery Scenarios (V, U, W, L)
5.6 Other Rare Diseases Segment Market Forecast, 2021-2031
5.6.1 Increasing government actions to increase awareness is likely to support market growth
5.6.2 Recovery Scenarios (V, U, W, L)
6 Rare Diseases Market by Type
6.1 Non Biologics Segment Market Forecast, 2021-2031
6.1.1 Small molecules approvals to fuel non biologics segment
6.1.2 Recovery Scenarios (V, U, W, L)
6.2 Biologics Segment Market Forecast, 2021-2031
6.2.1 Robust growth in number of new drug approvals to fuel biologics market
6.2.2 Recovery Scenarios (V, U, W, L)
7 Rare Diseases Market by Age
7.1 Adult Segment Market Forecast, 2021-2031
7.1.1 Rising number of cases foe Huntington, ALS, and Cancer to boost the segment growth
7.1.2 Recovery Scenarios (V, U, W, L)
7.2 Pediatric Segment Market Forecast, 2021-2031
7.2.1 Improving neonatal screening techniques to boost the segment growth
7.2.2 Recovery Scenarios (V, U, W, L)
8 Rare Diseases Market by End Use
8.1 Specialty Pharmacies Segment Market Forecast, 2021-2031
8.1.1 Adequate drug availability of drugs to fuel the segment
8.1.2 Recovery Scenarios (V, U, W, L)
8.2 Hospital Pharmacies Segment Market Forecast, 2021-2031
8.2.1 Large number of patients admitted to hospitals opt hospital pharmacies for procuring medicines
8.2.2 Recovery Scenarios (V, U, W, L)
8.3 Retail Pharmacies Segment Market Forecast, 2021-2031
8.3.1 Growing urbanization and expansion of retail pharmacy chains to fuel the segment growth
8.3.2 Recovery Scenarios (V, U, W, L)
9 Regional and Leading National Rare Diseases Market Forecasts 2021-2031
9.1 Global Rare Diseases Market by Region Forecast 2021-2031
9.2 Recovery Scenarios (V, U, W, L)
10 North America Rare Diseases Market
10.1 Well-developed healthcare infrastructure coupled with large number of approvals to fuel the market
10.2 North America Rare Diseases Market by Country, Forecast 2021-2031
10.3 U.S. Rare Diseases Market Forecast, 2021-2031
10.3.1 Large number of clinical trials to propel the market
10.3.2 Recovery Scenarios (V, U, W, L): U.S. Rare Diseases Market Forecast, 2021-2031
10.4 Canada Rare Diseases Market Forecast, 2021-2031
10.4.1 Increasing number of clinical trials within the country to fuel market growth
10.4.2 Recovery Scenarios (V, U, W, L): Canada Rare Diseases Market Forecast, 2021-2031
11 Europe Rare Diseases Market
11.1 Highly developed medical imaging sector to increase diagnosis of rare diseases to further propel drug sales
11.2 Europe Rare Diseases Market by Country, Forecast 2021-2031
11.3 Germany Rare Diseases Market Forecast, 2021-2031
11.3.1 Increasing community awareness to increase the market growth
11.3.2 Recovery Scenarios (V, U, W, L): Spain Rare Diseases Market Forecast, 2021-2031
11.4 UK Rare Diseases Market Forecast, 2021-2031
11.4.1 Rare disease framework to support market growth in near future
11.4.2 Recovery Scenarios (V, U, W, L): UK Rare Diseases Market Forecast, 2021-2031
11.5 France Rare Diseases Market Forecast, 2021-2031
11.5.1 Government support to favour the market growth
11.5.2 Recovery Scenarios (V, U, W, L): France Rare Diseases Market Forecast, 2021-2031
11.6 Italy Rare Diseases Market Forecast, 2021-2031
11.6.1 Pharmaceutical research and funding’s to propel market growth
11.6.2 Recovery Scenarios (V, U, W, L): Italy Rare Diseases Market Forecast, 2021-2031
11.7 Spain Rare Diseases Market Forecast, 2021-2031
11.7.1 Specific pricing policy to propel the growth
11.7.2 Recovery Scenarios (V, U, W, L): Spain Rare Diseases Market Forecast, 2021-2031
11.8 Russia Rare Diseases Market Forecast, 2021-2031
11.8.1 R&D to boost the Russian market in coming years
11.8.2 Recovery Scenarios (V, U, W, L): Russia Rare Diseases Market Forecast, 2021-2031
11.9 Denmark Rare Diseases Market Forecast, 2021-2031
11.9.1 Rising healthcare spending to increase drug penetration which in turn to fuel the market growth
11.9.2 Recovery Scenarios (V, U, W, L): Russia Rare Diseases Market Forecast, 2021-2031
11.10 Netherlands Rare Diseases Market Forecast, 2021-2031
11.10.1 Growing healthcare spending to fuel the demand for rare disease drugs
11.10.2 Recovery Scenarios (V, U, W, L): Netherlands Rare Diseases Market Forecast, 2021-2031
11.11 Rest of Europe Rare Diseases Market Forecast, 2021-2031
11.11.1 Growing prevalence of rare neurological diseases to drive the market growth
11.11.2 Recovery Scenarios (V, U, W, L): Rest of Europe Rare Diseases Market Forecast, 2021-2031
12 Asia Pacific Rare Diseases Market
12.1 Developing healthcare infrastructure to improve diagnosis rates
12.2 Asia Pacific Rare Diseases Market by Country, Forecast 2021-2031
12.3 Japan Rare Diseases Market Forecast, 2021-2031
12.3.1 Rising geriatric population to fuel the demand for drugs
12.3.2 Recovery Scenarios (V, U, W, L): Japan Rare Diseases Market Forecast, 2021-2031
12.4 China Rare Diseases Market Forecast, 2021-2031
12.4.1 Largest population base to create huge potential market for rare disease drugs
12.4.2 Recovery Scenarios (V, U, W, L): China Rare Diseases Market Forecast, 2021-2031
12.5 India Rare Diseases Market Forecast, 2021-2031
12.5.1 Rising prevalence of rare genetic diseases to propel growth in future
12.5.2 Recovery Scenarios (V, U, W, L): India Rare Diseases Market Forecast, 2021-2031
12.6 Rest of Asia Pacific Rare Diseases Market Forecast, 2021-2031
12.6.1 Progress in public awareness and investment opportunities to fuel the market growth
12.6.2 Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Rare Diseases Market Forecast, 2021-2031
13 Latin America Rare Diseases Market
13.1 Rising demand from brazil to increase regional market revenues
13.2 Latin America Rare Diseases Market by Country, Forecast 2021-2031
13.3 Brazil Rare Diseases Market Forecast, 2021-2031
13.3.1 Increasing number of approvals for orphan drugs to propel the country market
13.3.2 Recovery Scenarios (V, U, W, L): Brazil Rare Diseases Market Forecast, 2021-2031
13.4 Mexico Rare Diseases Market Forecast, 2021-2031
13.4.1 Transformation of current medical system predicted to improve market penetration for rare drugs
13.4.2 Recovery Scenarios (V, U, W, L): Mexico Rare Diseases Market Forecast, 2021-2031
13.5 Rest of Latin America Rare Diseases Market Forecast, 2021-2031
13.5.1 Improving healthcare infrastructure to fuel demand for rare drugs
13.5.2 Recovery Scenarios (V, U, W, L): Rest of Latin America Rare Diseases Market Forecast, 2021-2031
14 Middle East and Africa Rare Diseases Market
14.1 increasing awareness regarding rare disease to fuel market
14.2 Middle East and Africa Rare Diseases Market by Country, Forecast 2021-2031
14.3 UAE Rare Diseases Market Forecast, 2021-2031
14.3.1 Fastrack approvals with government support to fuel market growth
14.3.2 Recovery Scenarios (V, U, W, L): UAE Rare Diseases Market Forecast, 2021-2031
14.4 South Africa Rare Diseases Market Forecast, 2021-2031
14.4.1 Healthcare reforms are likely to increase demand for rare drugs
14.4.2 Recovery Scenarios (V, U, W, L): South Africa Rare Diseases Market Forecast, 2021-2031
14.5 Rest of Middle East and Africa Rare Diseases Market Forecast, 2021-2031
14.5.1 Improving healthcare infrastructure to increase rare drug availability
14.5.2 Recovery Scenarios (V, U, W, L): Rest of Middle East and Africa Rare Diseases Market Forecast, 2021-2031
15 Company Profiles
15.1 Pfizer Inc.
15.1.1 Company Overview
15.1.2 Products / Services
15.1.3 Financials, 2015-2019 (US$ billion, AGR %)
15.1.4 Mergers & Acquisitions (M&A) Activity
15.2 Novartis AG
15.2.1 Company Overview
15.2.2 Products / Services
15.2.3 Total Company Sales, 2015-2018
15.3 Merck KGaA
15.3.1 Company Overview
15.3.2 Products / Services
15.3.3 Financials, 2015-2019 (US$ billion, AGR %)
15.3.4 Mergers & Acquisitions (M&A) Activity
15.4 F. Hoffmann-La Roche Ltd.
15.4.1 Company Overview
15.4.2 Products / Services
15.4.3 Financials, 2015-2019 (US$ billion, AGR %)
15.5 Amgen Inc.
15.5.1 Company Overview
15.5.2 Products / Services
15.5.3 Financials, 2015-2019 (US$ billion, AGR %)
15.6 Biogen Inc.
15.6.1 Company Overview
15.6.2 Total Company Sales 2016 - 2019
15.6.3 Products / Services
15.6.4 Mergers & Acquisitions (M&A) Activity
15.7 Teva Pharmaceuticals
15.7.1 Company Overview
15.7.2 Total Company Sales 2016 - 2019
15.7.3 Products / Services
15.8 Alexion Pharmaceuticals, Inc.
15.8.1 Company Overview
15.8.2 Total Company Sales 2016 - 2019
15.8.3 Products / Services
15.9 Sanofi S.A.
15.9.1 Company Overview
15.9.2 Total Company Sales 2016 - 2019
15.9.3 Products / Services
15.10 Abbive
15.10.1 Company Overview
15.10.2 Total Company Sales 2016 - 2019
15.10.3 Products / Services
15.10.4 Mergers & Acquisitions (M&A) Activity
15.11 Bristol Myers Squibb
15.11.1 Company Overview
15.11.2 Total Company Sales 2016 - 2019
15.11.3 Products / Services
15.12 Takeda Pharmaceuticals
15.12.1 Company Overview
15.12.2 Total Company Sales 2017 - 2020
15.12.3 Products / Services
15.13 Roche
15.13.1 Company Overview
15.13.2 Total Company Sales 2016 - 2019
15.13.3 Products / Services
15.14 Johnson & Johnson Services, Inc.
15.14.1 Company Overview
15.14.2 Products / Services
15.14.3 Financials, 2015-2019 (US$ billion, AGR %)
15.14.4 Mergers & Acquisitions (M&A) Activity
16 Conclusion and Recommendations
16.1 Concluding Remarks
16.2 Recommendations
List of Tables
Table 1 Global Rare Diseases Market Snapshot, 2021 & 2030 (US$ billion, CAGR %)
Table 2 Pfizer Rare Disease Pipeline
Table 3 Genzyme Corporation Rare Disease Pipeline
Table 4 Takeda Rare Disease Pipeline
Table 5 Key Factors Affecting the Bargaining Power of Buyer
Table 6 Key Factors Affecting the Bargaining Power of Suppliers
Table 7 Key Factors Affecting the Threat of Substitutes
Table 8 Key Factors Affecting the Threat of New Entrants
Table 9 Key Factors Affecting the Industry Rivalry
Table 10 Global Rare Diseases Market Forecast by Disease, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 11 Global Rare Diseases Market Forecast by Revlimid, 2021-2031 (US$bn, AGR%, CAGR%)
Table 12 Global Rare Diseases Market Forecast by MabThera/Rituxan, 2021-2031 (US$bn, AGR%, CAGR%)
Table 13 Global Rare Diseases Market Forecast by Opdivo, 2021-2031 (US$bn, AGR%, CAGR%)
Table 14 Global Rare Diseases Market Forecast by Imbruvica, 2021-2031 (US$bn, AGR%, CAGR%)
Table 15 Global Rare Diseases Market Forecast by Sprycel, 2021-2031 (US$bn, AGR%, CAGR%)
Table 16 Global Rare Diseases Market Forecast by Avonex, 2021-2031 (US$bn, AGR%, CAGR%)
Table 17 Global Rare Diseases Market Forecast by Tasigna, 2021-2031 (US$bn, AGR%, CAGR%)
Table 18 Global Rare Diseases Market Forecast by Copaxone, 2021-2031 (US$bn, AGR%, CAGR%)
Table 19 Global Rare Diseases Market Forecast by Rebif, 2021-2031 (US$bn, AGR%, CAGR%)
Table 20 Global Rare Diseases Market Forecast by Gleevec, 2021-2031 (US$bn, AGR%, CAGR%)
Table 21 Global Rare Diseases Market Forecast by Velcade, 2021-2031 (US$bn, AGR%, CAGR%)
Table 22 Global Rare Diseases Market Forecast by Others, 2021-2031 (US$bn, AGR%, CAGR%)
Table 23 Global Rare Diseases Market Forecast by Disease, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 24 Global Rare Diseases Market Forecast by Rare Oncology Diseases, 2021-2031 (US$bn, AGR%, CAGR%)
Table 25 Global Rare Diseases Market Forecast by Rare Oncology Diseases, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 26 Global Rare Diseases Market Forecast by Rare Oncology Diseases, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 27 Global Rare Diseases Market Forecast by Rare Oncology Diseases, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 28 Global Rare Diseases Market Forecast by Rare Oncology Diseases, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 29 Global Rare Diseases Market Forecast by Rare Metabolic Diseases , 2021-2031 (US$bn, AGR%, CAGR%)
Table 30 Global Rare Diseases Market Forecast by Rare Metabolic Diseases , 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 31 Global Rare Diseases Market Forecast by Rare Metabolic Diseases , 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 32 Global Rare Diseases Market Forecast by Rare Metabolic Diseases , 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 33 Global Rare Diseases Market Forecast by Rare Metabolic Diseases , 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 34 Global Rare Diseases Market Forecast by Rare Neurologic Diseases , 2021-2031 (US$bn, AGR%, CAGR%)
Table 35 Global Rare Diseases Market Forecast by Rare Neurologic Diseases , 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 36 Global Rare Diseases Market Forecast by Rare Neurologic Diseases , 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 37 Global Rare Diseases Market Forecast by Rare Neurologic Diseases , 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 38 Global Rare Diseases Market Forecast by Rare Neurologic Diseases , 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 39 Global Rare Diseases Market Forecast by Rare Hematology Diseases , 2021-2031 (US$bn, AGR%, CAGR%)
Table 40 Global Rare Diseases Market Forecast by Rare Hematology Diseases , 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 41 Global Rare Diseases Market Forecast by Rare Hematology Diseases , 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 42 Global Rare Diseases Market Forecast by Rare Hematology Diseases , 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 43 Global Rare Diseases Market Forecast by Rare Hematology Diseases , 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 44 Global Rare Diseases Market Forecast by Rare Infectious Diseases , 2021-2031 (US$bn, AGR%, CAGR%)
Table 45 Global Rare Diseases Market Forecast by Rare Infectious Diseases , 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 46 Global Rare Diseases Market Forecast by Rare Infectious Diseases , 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 47 Global Rare Diseases Market Forecast by Rare Infectious Diseases , 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 48 Global Rare Diseases Market Forecast by Rare Infectious Diseases , 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 49 Global Rare Diseases Market Forecast by Other Rare Diseases , 2021-2031 (US$bn, AGR%, CAGR%)
Table 50 Global Rare Diseases Market Forecast by Other Rare Diseases, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 51 Global Rare Diseases Market Forecast by Other Rare Diseases , 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 52 Global Rare Diseases Market Forecast by Other Rare Diseases , 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 53 Global Rare Diseases Market Forecast by Other Rare Diseases , 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 54 Global Rare Diseases Market Forecast by non-biologics, 2021-2031 (US$bn, AGR%, CAGR%)
Table 55 Global Rare Diseases Market Forecast by non-biologics, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 56 Global Rare Diseases Market Forecast by non-biologics, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 57 Global Rare Diseases Market Forecast by non-biologics, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 58 Global Rare Diseases Market Forecast by non-biologics, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 59 Global Rare Diseases Market Forecast by Biologics, 2021-2031 (US$bn, AGR%, CAGR%)
Table 60 Global Rare Diseases Market Forecast by Biologics, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 61 Global Rare Diseases Market Forecast by Biologics, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 62 Global Rare Diseases Market Forecast by Biologics, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 63 Global Rare Diseases Market Forecast by Biologics, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 64 Global Rare Diseases Market Forecast by Type, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 65 Global Rare Diseases Market Forecast by Adult, 2021-2031 (US$bn, AGR%, CAGR%)
Table 66 Global Rare Diseases Market Forecast by Adult, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 67 Global Rare Diseases Market Forecast by Adult, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 68 Global Rare Diseases Market Forecast by Adult, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 69 Global Rare Diseases Market Forecast by Adult, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 70 Global Rare Diseases Market Forecast by Pediatric, 2021-2031 (US$bn, AGR%, CAGR%)
Table 71 Global Rare Diseases Market Forecast by Pediatric, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 72 Global Rare Diseases Market Forecast by Pediatric, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 73 Global Rare Diseases Market Forecast by Pediatric, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 74 Global Rare Diseases Market Forecast by Pediatric, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 75 Global Rare Diseases Market Forecast by Specialty Pharmacies, 2021-2031 (US$bn, AGR%, CAGR%)
Table 76 Global Rare Diseases Market Forecast by Specialty Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 77 Global Rare Diseases Market Forecast by Specialty Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 78 Global Rare Diseases Market Forecast by Specialty Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 79 Global Rare Diseases Market Forecast by Specialty Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 80 Global Rare Diseases Market Forecast by Hospital Pharmacies, 2021-2031 (US$bn, AGR%, CAGR%)
Table 81 Global Rare Diseases Market Forecast by Hospital Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 82 Global Rare Diseases Market Forecast by Hospital Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 83 Global Rare Diseases Market Forecast by Hospital Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 84 Global Rare Diseases Market Forecast by Hospital Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 85 Global Rare Diseases Market Forecast by Retail Pharmacies, 2021-2031 (US$bn, AGR%, CAGR%)
Table 86 Global Rare Diseases Market Forecast by Retail Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 87 Global Rare Diseases Market Forecast by Retail Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 88 Global Rare Diseases Market Forecast by Retail Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 89 Global Rare Diseases Market Forecast by Retail Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 90 Global Rare Diseases Market Forecast by Region, 2021-2031 (US$bn, AGR%, CAGR%)
Table 91 Global Rare Diseases Market Forecast by Country, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 92 Global Rare Diseases Market Forecast by Country, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 93 Global Rare Diseases Market Forecast , 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 94 Global Rare Diseases Market Forecast , 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 95 U.S. clinical trial landscape for rare disease, 2021
Table 96 U.S. Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 97 U.S. Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 98 U.S. Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 99 U.S. Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 100 U.S. Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 101 Canada clinical trial landscape for rare diseases, 2021
Table 102 Canada Rare Diseases Market Forecast by Country, 2021-2031 (US$bn, AGR%, CAGR%)
Table 103 Canada Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 104 Canada Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 105 Canada Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 106 Canada Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 107 List of drugs used in treating rare diseases
Table 108 Germany Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 109 Germany Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 110 Germany Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 111 Germany Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 112 Germany Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 113 UK Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 114 UK Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 115 UK Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 116 UK Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 117 UK Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 118 France Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 119 France Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 120 France Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 121 France Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 122 France Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 123 Italy Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 124 Italy Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 125 Italy Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 126 Italy Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 127 Italy Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 128 Spain Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 129 Spain Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 130 Spain Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 131 Spain Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 132 Spain Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 133 Russia Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 134 Russia Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 135 Russia Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 136 Russia Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 137 Russia Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 138 Denmark Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 139 Denmark Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 140 Denmark Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 141 Denmark Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 142 Denmark Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 143 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 144 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 145 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 146 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 147 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 148 ROEu Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 149 ROEu Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 150 ROEu Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 151 ROEu Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 152 ROEu Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 153 National initiatives to support rare diseases and access to orphan drugs
Table 154 Japan Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 155 Japan Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 156 Japan Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 157 Japan Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 158 Japan Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 159 China Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 160 China Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 161 China Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 162 China Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 163 China Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 164 India Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 165 India Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 166 India Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 167 India Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 168 India Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 169 RoAPAC Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 170 RoAPAC Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 171 RoAPAC Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 172 RoAPAC Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 173 RoAPAC Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 174 National Laws on Rare Diseases in 6 Latin American Countries
Table 175 Brazil Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 176 Brazil Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 177 Brazil Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 178 Brazil Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 179 Brazil Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 180 Mexico Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 181 Mexico Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 182 Mexico Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 183 Mexico Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 184 Mexico Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 185 ROLATAM Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 186 ROLATAM Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 187 ROLATAM Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 188 ROLATAM Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 189 ROLATAM Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 190 UAE Medicines with Fast Track Registration
Table 191 UAE Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 192 UAE Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 193 UAE Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 194 UAE Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 195 UAE Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 196 South Africa Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 197 South Africa Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 198 South Africa Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 199 South Africa Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 200 South Africa Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 201 RoMEA Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Table 202 RoMEA Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “V” Shaped Recovery
Table 203 RoMEA Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “U” Shaped Recovery
Table 204 RoMEA Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “W” Shaped Recovery
Table 205 RoMEA Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): “L” Shaped Recovery
Table 206 Pfizer Inc. Profile 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 207 Pfizer Products / Services
Table 208 Pfizer Total Company Sales, 2015-2019 (US$ million, AGR %)
Table 209 Novartis AG Profile 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 210 Novartis AG Products / Services
Table 211 Novartis AG Total Company Sales, 2015-2019 (US$ million, AGR %)
Table 212 Merck KGaA Profile 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 213 Merck KGaA Products / Services
Table 214 Merck KGaA Total Company Sales, 2015-2019 (US$ million, AGR %)
Table 215 F. Hoffmann-La Roche Ltd. Profile 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 216 F. Hoffmann-La Roche Ltd Products / Services
Table 217 F. Hoffmann-La Roche Ltd Total Company Sales, 2015-2019 (US$ million, AGR %)
Table 218 Amgen Inc. Profile 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 219 Amgen Inc.Products / Services
Table 220 Amgen Inc.Total Company Sales, 2015-2019 (US$ million, AGR %)
Table 221 Amgen Inc. Company overview
Table 222 Amgen Inc. Products / Services
Table 223 Teva Pharmaceuticals Company overview
Table 224 Teva Pharmaceuticals Total Company Sales, 2015-2019 (US$ million, AGR %)
Table 225 Teva Pharmaceuticals Products / Services
Table 226 Alexion Pharmaceuticals, Inc Company overview
Table 227 Alexion Pharmaceuticals, Inc Total Company Sales, 2015-2019 (US$ million, AGR %)
Table 228 Alexion Pharmaceuticals, Inc Products / Services
Table 229 Sanofi S.A. Company overview
Table 230 Sanofi S.A. Total Company Sales, 2015-2019 (US$ million, AGR %)
Table 231 Sanofi S.A. Products / Services
Table 232 Abbive Company overview
Table 233 Abbive Total Company Sales 2016 – 2019
Table 234 Abbive Total Company Sales, 2015-2019 (US$ million, AGR %)
Table 235 Abbive Products / Services
Table 236 Bristol Myers Squibb Company overview
Table 237 Bristol Myers Squibb Total Company Sales, 2015-2019 (US$ million, AGR %)
Table 238 Bristol Myers Squibb Products / Services
Table 239 Company overview
Table 240 Takeda Pharmaceuticals Total Company Sales, 2017 - 2020 (US$ million, AGR %)
Table 241 Takeda Pharmaceuticals Products / Services
Table 242 Roche Company overview
Table 243 Roche Total Company Sales, 2017 - 2020 (US$ million, AGR %)
Table 244 Roche Products / Services
Table 245 Johnson & Johnson Services, Inc. Profile 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 246 Johnson & Johnson Services, Inc Products / Services
Table 247 Johnson & Johnson Services, Inc Total Company Sales 2015-2019 (US$ million, AGR %)
List of Figures
Figure 1 Global Rare Diseases Market: Market Segmentation
Figure 2 Global Rare Diseases Market: Market Trends
Figure 3 CDER’s Annual Novel Drug Approvals: 2011 – 2020
Figure 4 Global Rare Disease Market: SWOT Analysis
Figure 5 Global Rare Disease Market: Porter’s Five Forces Analysis
Figure 6 Global Rare Diseases Market Forecast by Drugs, 2021-2031 (US$ billion, AGR %)
Figure 7 Global Rare Diseases Market Share Forecast by Drugs, 2021, 2026, 2031 (%)
Figure 8 Global Rare Diseases Market for Revlimid Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 9 Global Rare Diseases Market for MabThera/Rituxan Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 10 Global Rare Diseases Market for Opdivo Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 11 Global Rare Diseases Market for Imbruvica Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 12 Global Rare Diseases Market for Sprycel Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 13 Global Rare Diseases Market for Avonex Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 14 Global Rare Diseases Market for Tasigna Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 15 Global Rare Diseases Market for Copaxone Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 16 Global Rare Diseases Market for Rebif Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 17 Global Rare Diseases Market for Gleevec Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 18 Global Rare Diseases Market for Velcade Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 19 Global Rare Diseases Market for Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 20 Global Rare Diseases Market Forecast by Disease, 2021-2031 (US$ billion, AGR %)
Figure 21 Global Rare Diseases Market Share Forecast by Disease, 2021, 2026, 2031 (%)
Figure 22 Global Rare Diseases Market for Rare Oncology Diseases Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 23 Global Rare Diseases Market for Rare Oncology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 24 Global Rare Diseases Market for Rare Oncology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 25 Global Rare Diseases Market for Rare Oncology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 26 Global Rare Diseases Market for Rare Oncology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 27 Global Rare Diseases Market for Rare Metabolic Diseases Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 28 Global Rare Diseases Market for Rare Metabolic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 29 Global Rare Diseases Market for Rare Metabolic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 30 Global Rare Diseases Market for Rare Metabolic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 31 Global Rare Diseases Market for Rare Metabolic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 32 Global Rare Diseases Market for Rare Neurologic Diseases Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 33 Global Rare Diseases Market for Rare Neurologic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 34 Global Rare Diseases Market for Rare Neurologic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 35 Global Rare Diseases Market for Rare Neurologic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 36 Global Rare Diseases Market for Rare Neurologic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 37 Global Rare Diseases Market for Rare Hematology Diseases Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 38 Global Rare Diseases Market for Rare Hematology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 39 Global Rare Diseases Market for Rare Hematology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 40 Global Rare Diseases Market for Rare Hematology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 41 Global Rare Diseases Market for Rare Hematology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 42 Global Rare Diseases Market for Rare Infectious Diseases Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 43 Global Rare Diseases Market for Rare Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 44 Global Rare Diseases Market for Rare Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 45 Global Rare Diseases Market for Rare Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 46 Global Rare Diseases Market for Rare Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 47 Global Rare Diseases Market for Other Rare Diseases Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 48 Global Rare Diseases Market for Other Rare Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 49 Global Rare Diseases Market for Other Rare Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 50 Global Rare Diseases Market for Other Rare Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 51 Global Rare Diseases Market for Other Rare Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 52 Global Rare Diseases Market Forecast by Type, 2021-2031 (US$ billion, AGR %)
Figure 53 Global Rare Diseases Market Share Forecast by Type, 2021, 2026, 2031 (%)
Figure 54 Global Rare Diseases Market for Non Biologics Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 55 Global Rare Diseases Market for Non Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 56 Global Rare Diseases Market for Non Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 57 Global Rare Diseases Market for Non Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 58 Global Rare Diseases Market for Non Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 59 Global Rare Diseases Market for Biologics Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 60 Global Rare Diseases Market for Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 61 Global Rare Diseases Market for Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 62 Global Rare Diseases Market for Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 63 Global Rare Diseases Market for Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 64 Global Rare Diseases Market Forecast by Age, 2021-2031 (US$ billion, AGR %)
Figure 65 Global Rare Diseases Market Share Forecast by Age, 2021, 2026, 2031 (%)
Figure 66 Global Rare Diseases Market for Adult Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 67 Global Rare Diseases Market for Adult Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 68 Global Rare Diseases Market for Adult Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 69 Global Rare Diseases Market for Adult Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 70 Global Rare Diseases Market for Adult Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 71 Global Rare Diseases Market for Pediatric Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 72 Global Rare Diseases Market for Pediatric Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 73 Global Rare Diseases Market for Pediatric Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 74 Global Rare Diseases Market for Pediatric Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 75 Global Rare Diseases Market for Pediatric Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 76 Global Rare Diseases Market Forecast by End Use, 2021-2031 (US$ billion, AGR %)
Figure 77 Global Rare Diseases Market Share Forecast by End Use, 2021, 2026, 2031 (%)
Figure 78 Global Rare Diseases Market for Specialty Pharmacies Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 79 Global Rare Diseases Market for Specialty Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 80 Global Rare Diseases Market for Specialty Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 81 Global Rare Diseases Market for Specialty Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 82 Global Rare Diseases Market for Specialty Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 83 Global Rare Diseases Market for Hospital Pharmacies Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 84 Global Rare Diseases Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 85 Global Rare Diseases Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 86 Global Rare Diseases Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 87 Global Rare Diseases Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 88 Global Rare Diseases Market for Retail Pharmacies Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 89 Global Rare Diseases Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 90 Global Rare Diseases Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 91 Global Rare Diseases Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 92 Global Rare Diseases Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 93 Global Rare Diseases Market Forecast by Region 2021-2031 (US$ billion)
Figure 94 Global Rare Diseases Market Share Forecast by Region 2021, 2026, 2031 (%)
Figure 95 Global Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 96 Global Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 97 Global Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 98 Global Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 99 North America Rare Diseases Market Forecast by Country 2021-2031 (US$ billion)
Figure 100 North America Rare Diseases Market Share Forecast by Country 2021, 2026, 2031 (%)
Figure 101 U.S. Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 102 U.S. Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 103 U.S. Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 104 U.S. Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 105 U.S. Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 106 Canada Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 107 Canada Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 108 Canada Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 109 Canada Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 110 Canada Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 111 Europe Rare Diseases Market Forecast by Country 2021-2031 (US$ billion)
Figure 112 Europe Rare Diseases Market Share Forecast by Country 2021, 2026, 2031 (%)
Figure 113 Germany Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 114 Germany Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 115 Germany Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 116 Germany Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 117 Germany Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 118 UK Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 119 UK Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 120 UK Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 121 UK Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 122 UK Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 123 France Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 124 France Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 125 France Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 126 France Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 127 France Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 128 Italy Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 129 Italy Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 130 Italy Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 131 Italy Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 132 Italy Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 133 Spain Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 134 Spain Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 135 Spain Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 136 Spain Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 137 Spain Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 138 Russia Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 139 Russia Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 140 Russia Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 141 Russia Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 142 Russia Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 143 Denmark Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 144 Denmark Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 145 Denmark Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 146 Denmark Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 147 Denmark Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 148 Netherlands Rare Diseases Market Forecast by Country, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 149 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 150 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 151 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 152 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 153 ROEu Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 154 Rest of Europe Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 155 Rest of Europe Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 156 Rest of Europe Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 157 Rest of Europe Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 158 Asia Pacific Rare Diseases Market Forecast by Country 2021-2031 (US$ billion)
Figure 159 Asia Pacific Rare Diseases Market Share Forecast by Country 2021, 2026, 2031 (%)
Figure 160 Japan Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 161 Japan Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 162 Japan Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 163 Japan Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 164 Japan Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 1 China Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 165 China Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 166 China Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 167 China Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 168 China Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 169 Disease-associated founder variations prevalent in India
Figure 170 India Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 171 India Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 172 India Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 173 India Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 174 India Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 175 RoAPAC Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 176 Rest of Asia Pacific Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 177 Rest of Asia Pacific Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 178 Rest of Asia Pacific Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 179 Rest of Asia Pacific Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 180 Latin America Rare Diseases Market Forecast by Country 2021-2031 (US$ billion)
Figure 181 Latin America Rare Diseases Market Share Forecast by Country 2021, 2026, 2031 (%)
Figure 1 Brazil Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 182 Brazil Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 183 Brazil Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 184 Brazil Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 185 Brazil Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 186 Mexico Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 187 Mexico Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 188 Mexico Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 189 Mexico Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 190 Mexico Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 1 ROLATAM Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 191 Rest of Latin America Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 192 Rest of Latin America Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 193 Rest of Latin America Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 194 Rest of Latin America Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 195 Orphan disease likely coverage across MENA regions based on current environment
Figure 196 Middle East and Africa Rare Diseases Market Forecast by Country 2021-2031 (US$ billion)
Figure 197 Middle East and Africa Rare Diseases Market Share Forecast by Country 2021, 2026, 2031 (%)
Figure 198 UAE Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 199 UAE Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 200 UAE Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 201 UAE Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 202 UAE Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 203 South Africa Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 204 South Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 205 South Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 206 South Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 207 South Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 208 RoMEA Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
Figure 209 Rest of Middle East and Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 210 Rest of Middle East and Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 211 Rest of Middle East and Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 212 Rest of Middle East and Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 213 Pfizer Total Company Sales, 2015-2019 (US$ million, AGR %)
Figure 214 Novartis AG Total Company Sales 2015-2018 (US$ million, AGR %)
Figure 215 Merck KGaA Total Company Sales, 2015-2019 (US$ million, AGR %)
Figure 216 F. Hoffmann-La Roche Ltd Total Company Sales, 2015-2019 (US$ million, AGR %)
Figure 217 Amgen Inc.Total Company Sales, 2015-2019 (US$ million, AGR %)
Figure 218 Amgen Inc.Total Company Sales 2016 – 2019
Figure 219 Teva Pharmaceuticals Total Company Sales 2016 – 2019
Figure 220 Alexion Pharmaceuticals, Inc Total Company Sales 2016 – 2019
Figure 221 Sanofi S.A. Total Company Sales 2016 – 2019
Figure 222 Bristol Myers Squibb Total Company Sales 2016 – 2019
Figure 223 Takeda Pharmaceuticals Total Company Sales 2017 – 2020
Figure 224 Roche Total Company Sales 2016 – 2019
Figure 225 Johnson & Johnson Services, Inc Total Company Sales (US$ million, AGR %)
Figure 226 Global Rare Diseases Market Forecast by Region 2021-2031 (US$ billion)
Companies Profiled in the Report
AbbVie
Alexion Pharmaceuticals, Inc.
Amgen Inc.
Biogen Inc.
Bristol Myers Squibb
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services, Inc.
Merck KGaA
Novartis AG
Pfizer Inc.
Roche
Sanofi S.A.
Takeda Pharmaceuticals
Teva Pharmaceuticals
List of Other Companies in the Global Rare Diseases Market
3billion
Aeglea BioTherapeutics
Agios Pharmaceuticals
AGTC (Applied Genetics Technology Corp)
Akcea Therapeutics
Alexion
Allievex
Amicus Therapeutics
Amryt Pharma
Apic Bio
Ascendis Pharma
Attune Pharmaceuticals
Azafaros
BioCryst Pharmaceuticals
BioMarin Pharmaceuticals
BioXcel Therapeutics
CureVac
Emmaus
Harmony Biosciences
Levo Therapeutics
List of Organizations
APEC LSIF Rare Disease Network
Asia Pacific Alliance of Rare Disease Organisations (APARDO)
ERA-Net for Research Programmes on Rare Diseases (E-Rare)
European Organisation for Rare Diseases (EURORDIS)
European Platform for Rare Disease Registries (EPIRARE)
European Union Committee of Experts on Rare Diseases (EUCERD)
Global Commission to End the Diagnostic Odyssey for Children
INNOVCare
International Coalition of Organizations Supporting Endocrine Patients (ICOSEP)
International Conference on Rare Diseases & Orphan Drugs (ICORD)
International Rare Diseases Research Consortium (IRDiRC)
National Organization for Rare Disorders
NGO Committee for Rare Diseases
Organization For Rare Diseases India
Orphanet
Rare Disease Day
Rare Diseases International (RDI)
RareConnect
RD-Connect
The World Association of Cured Rare Diseases (WACRD)
The World Association of Orphan Diseases (WAO(R)D)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
